在刚果民主共和国金沙萨的2型糖尿病患者中改善血糖控制的潜在干预措施的共识:Delphi研究
Jean-Pierre Fina Lubaki1,2, Olufemi Babatunde Omole1, Joel Msafiri Francis1
1Department of Family Medicine and Primary Care, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Global health action
|August 25, 2023
概括
专家们就39项干预措施达成共识,以改善刚果民主共和国金沙萨的2型糖尿病患者的血糖控制,解决卫生系统和患者支持问题.
科学领域:
- 公共卫生 公共卫生
- 内分泌学 在内分泌学.
- 糖尿病管理 糖尿病管理
背景情况:
- 低血糖控制是刚果民主共和国的一个重大健康问题,观察到的高率.
- 现有的临床和经济影响是严重的,但没有政策框架指导干预.
- 在金沙萨,2型糖尿病的管理面临挑战,需要有针对性的战略.
研究的目的:
- 在专家之间就改善2型糖尿病患者血糖控制的有效干预措施达成共识.
- 在刚果民主共和国金沙萨解决改善糖尿病护理的急需问题.
主要方法:
- 与31位本地和5位国际专家进行了两轮电子Delphi研究.
- 专家们使用4利克尔特尺度问卷评估了建议的干预措施,并提供了额外的建议.
- 统计分析包括每个声明的模式,平均值和标准偏差计算.
主要成果:
- 在五个关键领域的39个声明上达成共识.
- 这些领域包括加强卫生系统,提高糖尿病意识,减轻经济负担.
- 其他共识领域包括促进生活方式的改变和减少未被诊断的糖尿病.
结论:
- 改善血糖控制需要在非传染性疾病管理中采取综合方法.
- 一个协调和更好地资助的医疗保健系统对于成功实施至关重要.
- 需要进一步的研究,以有效地运行和实施已确定的干预措施.
相关概念视频
Diabetes: Management and Pharmacotherapy
310
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
310
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
205
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
205
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K


